BERGEN, Norway, June 23, 2020 /PRNewswire/ -- BerGenBio, a
clinical-stage biopharmaceutical company developing novel,
selective AXL kinase inhibitors for multiple cancer indications
today announces that Richard
Godfrey, CEO plans to present an overview of the Company at
the upcoming Virtual European Biotech Investor Day 2020 hosted
by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq. During
the 30 minute presentation, participants will be able to submit
questions electronically with answers provided at the discretion of
the Company on an individual basis afterwards.
Date and time: Thursday June 25, at 1:00 p.m. EDT (7:00 p.m.
CET).
View and attend the event
online: www.webcaster4.com/Webcast/Page/2408/35370
The presentation will also be made available on the Company's
website after the event has ended on 25 June at
www.bergenbio.com/investors/presentations/
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II oncology
clinical development programme focused on combination and single
agent therapy in lung cancer, leukaemia and COVID19. A
first-in-class functional blocking anti-AXL antibody, tilvestamab,
is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient
populations most likely to benefit from bemcentinib: this is
expected to facilitate more efficient registration trials
supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
About AXL
AXL kinase is a cell membrane receptor and an essential mediator
of the biological mechanisms underlying life-threatening diseases.
In cancer, AXL suppresses the body's immune response to tumours and
drives cancer treatment failure across many indications. AXL
expression defines a very poor prognosis subgroup in most cancers.
AXL inhibitors, therefore, have potential high value at the centre
of cancer combination therapy, addressing significant unmet medical
needs and multiple high-value market opportunities. Research has
also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme. Ongoing clinical trials are investigating
bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including
immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular
catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity. Increase in AXL function has been linked to
key mechanisms of drug resistance and immune escape by tumour
cells, leading to aggressive metastatic cancers.
Contacts
Richard
Godfrey
CEO, BerGenBio ASA
+47-917-86-304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513
International Media Relations
Mary-Jane Elliott, Chris
Welsh, Lucy Featherstone,
Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44-20-3709-5700
Media Relations in Norway
Jan
Petter Stiff, Crux Advisers
stiff@crux.no
+47-995-13-891
This information was brought to you by Cision
http://news.cision.com